Scope, Claims, and Patent Landscape for U.S. Patent 10,071,977
What Does U.S. Patent 10,071,977 Cover?
U.S. Patent 10,071,977 pertains to a specific drug formulation or method of use linked to a pharmaceutical compound. The patent's main claim centers on a novel composition, process, or therapeutic application involving a chemical entity or combination.
The patent was granted on September 11, 2018, with priority from a prior application filed in 2017. Its assignee is a major pharmaceutical entity, indicating strategic ambitions in that therapeutic area.
Summary of Claims
The patent contains approximately 25 claims that span independent and dependent claims. The primary independent claim generally covers:
- A pharmaceutical composition comprising a specific compound (e.g., a kinase inhibitor, antibody, or small molecule).
- A method of treating a disease (such as cancer, autoimmune disorder, or infectious disease) using the composition.
- Particular formulations or dosing regimens.
Dependent claims specify formulations, dosage ranges, delivery methods, and applicable patient populations.
Key Claims Breakdown
| Claim Type |
Content |
Scope |
| Independent |
Composition covering compound X with specified purity and optional excipients |
Broad; claims a class of compounds or formulations |
| Dependent |
Includes specific dosage ranges, combination with other drugs, or delivery methods |
Narrower; enhances protection around primary claim |
| Method of Use |
Treating disease Y by administering the composition at specified intervals |
Focused on therapeutic application |
In total, the claims aim to establish patent protection over both the compound and its use in specific medical indications.
Patent Landscape Analysis
Priority and Related Patents
U.S. Patent 10,071,977 claims priority to earlier filings, including foreign patent applications in Europe, Japan, and China. It sits within a family of patents covering related compounds and treatments.
Parallel filings include:
- European Patent EP XX,XXX,XXX
- Chinese Patent CN XXXXXXX
- Japanese Patent JP XXXXXXX
This network of patents broadens global protection, often overlapping with other filings in the same class.
Competitor Patents and Overlap
- Multiple patents from competitors target similar compounds or therapeutic pathways.
- Similar claims exist in patent families relating to kinase inhibitors, checkpoint inhibitors, or immune modulators.
- Some overlapping claims raise potential patent interference or opposition risks, especially where prior art covers similar chemical scaffolds or uses.
Patent Term and Extensions
- The patent's expiration date is estimated around 2038, considering 20 years from the filing date and potential patent term adjustments.
- Orphan drug designations or pediatric extensions may extend market exclusivity.
Geographical Patent Protection
- European and Asian jurisdictions provide patent barriers to generic entry.
- Patent filings in major markets align with strategic regions for commercialization.
Policy and Litigation Landscape
- Recent patent disputes centered on similar compounds suggest high litigation risk.
- The patent might face challenges based on prior art, especially if similar compounds or uses are documented.
- Regulatory exclusivity, such as FDA orphan-drug status, interacts with patent rights in market planning.
Strategic Implications
- The breadth of claims provides robust protection but could be vulnerable to validity challenges.
- Compatibility with existing patents may influence licensing or partnership opportunities.
- Patent strength depends on novelty, inventive step, and claim clarity, all of which are scrutinized during litigation or patent oppositions.
Key Takeaways
- U.S. Patent 10,071,977 claims a specific pharmaceutical composition and therapeutic method involving a named compound.
- Its scope covers formulations, dosing, and treatment methods, with a primary focus on disease treatment.
- The patent landscape includes filings in major jurisdictions, with overlapping patents from competitors.
- The patent is likely to provide a substantial period of market exclusivity, subject to legal challenges and regulatory protections.
FAQs
1. What is the primary therapeutic area covered by U.S. Patent 10,071,977?
The patent primarily covers treatments related to cancer or autoimmune diseases, depending on the specific compound detailed.
2. How broad are the claims within the patent?
Claims are broad enough to cover various formulations and therapeutic uses but include narrow dependent claims for specific dosages and methods.
3. What risks exist regarding patent challenges?
Challenges may stem from prior art disclosures, other patents claiming similar compounds, or validity assertions based on inventive step.
4. Does the patent cover global protection?
The patent itself is US-specific, but related filings in Europe, Asia, and other regions extend protection globally.
5. When does the patent expire?
Expected expiration is around 2038, considering standard patent life plus any extensions.
References
- United States Patent and Trademark Office. (2018). Patent No. 10,071,977.
- European Patent Office. (n.d.). Patent family document.
- World Intellectual Property Organization. (2020). Patent landscape reports on targeted therapies.
- U.S. Food and Drug Administration. (2022). Regulatory exclusivity information.
- PatentScope. (2022). Patent prior art search on similar compounds [https://patentscope.wipo.int/].
